Tumor-targeted glycogen nanoparticles loaded with hemin and glucose oxidase to promote tumor synergistic therapy
Copyright © 2023. Published by Elsevier B.V..
Strategies which are used to address the low levels of intracellular hydrogen peroxide and the development of biocompatible catalysts still need to be fulfilled in tumor chemodynamic therapy. Therefore, a novel tumor-targeted glycogen-based nanoparticle system (GN/He/GOx/HA) was developed to co-deliver hemin (He) and GOx, which can self-supply glucose formed upon degradation of glycogen by α-glycosidase in the lysosome environment, in order to achieve synergistic antitumor therapy. Hyaluronic acid (HA) was selected as the outer shell to protect the activity of GOx, and to increase the uptake by tumor cells via CD44 receptor-mediated endocytosis. GN/He/GOx/HA NPs had a good stability in the blood circulation, but fast release of the therapeutic cargos upon intracellular uptake. Hemin had a cascade catalytic reaction with GOx. Furthermore, GN/He/GOx/HA NPs had the strongest cytotoxicity in Hela cells in a glucose concentration dependent manner. The NPs could efficiently produce reactive oxygen species in tumor cells, resulting in a decrease in the mitochondrial membrane potential and apoptosis of tumor cells. The in vivo results showed that the drug-loaded nanoparticles had good safety, biocompatibility, and efficacious antitumor effect. Therefore, the glycogen-based nanoparticle delivery system provides potential application for self-enhancing CDT, which can be used for effective antitumor therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:239 |
|---|---|
| Enthalten in: |
International journal of biological macromolecules - 239(2023) vom: 01. Juni, Seite 124363 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qiu, Lipeng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
743LRP9S7N |
|---|
| Anmerkungen: |
Date Completed 19.05.2023 Date Revised 19.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijbiomac.2023.124363 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355364298 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355364298 | ||
| 003 | DE-627 | ||
| 005 | 20231226064206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijbiomac.2023.124363 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355364298 | ||
| 035 | |a (NLM)37031790 | ||
| 035 | |a (PII)S0141-8130(23)01257-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qiu, Lipeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor-targeted glycogen nanoparticles loaded with hemin and glucose oxidase to promote tumor synergistic therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2023 | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a Strategies which are used to address the low levels of intracellular hydrogen peroxide and the development of biocompatible catalysts still need to be fulfilled in tumor chemodynamic therapy. Therefore, a novel tumor-targeted glycogen-based nanoparticle system (GN/He/GOx/HA) was developed to co-deliver hemin (He) and GOx, which can self-supply glucose formed upon degradation of glycogen by α-glycosidase in the lysosome environment, in order to achieve synergistic antitumor therapy. Hyaluronic acid (HA) was selected as the outer shell to protect the activity of GOx, and to increase the uptake by tumor cells via CD44 receptor-mediated endocytosis. GN/He/GOx/HA NPs had a good stability in the blood circulation, but fast release of the therapeutic cargos upon intracellular uptake. Hemin had a cascade catalytic reaction with GOx. Furthermore, GN/He/GOx/HA NPs had the strongest cytotoxicity in Hela cells in a glucose concentration dependent manner. The NPs could efficiently produce reactive oxygen species in tumor cells, resulting in a decrease in the mitochondrial membrane potential and apoptosis of tumor cells. The in vivo results showed that the drug-loaded nanoparticles had good safety, biocompatibility, and efficacious antitumor effect. Therefore, the glycogen-based nanoparticle delivery system provides potential application for self-enhancing CDT, which can be used for effective antitumor therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chemodynamic therapy | |
| 650 | 4 | |a Glucose oxidase | |
| 650 | 4 | |a Glycogen | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Glucose Oxidase |2 NLM | |
| 650 | 7 | |a EC 1.1.3.4 |2 NLM | |
| 650 | 7 | |a Hemin |2 NLM | |
| 650 | 7 | |a 743LRP9S7N |2 NLM | |
| 650 | 7 | |a Glycogen |2 NLM | |
| 650 | 7 | |a 9005-79-2 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Hydrogen Peroxide |2 NLM | |
| 650 | 7 | |a BBX060AN9V |2 NLM | |
| 700 | 1 | |a Wang, Junze |e verfasserin |4 aut | |
| 700 | 1 | |a Conceição, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shenhuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Meiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Weijun |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Miaomiao |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Xian |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Matthew J A |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jinghua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of biological macromolecules |d 1992 |g 239(2023) vom: 01. Juni, Seite 124363 |w (DE-627)NLM012627356 |x 1879-0003 |7 nnns |
| 773 | 1 | 8 | |g volume:239 |g year:2023 |g day:01 |g month:06 |g pages:124363 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijbiomac.2023.124363 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 239 |j 2023 |b 01 |c 06 |h 124363 | ||